IMMUNE-ONC THERAPEUTICS, INC.
Palo Alto, CA · Founded 2015 · CIK 0001685307 · Biotech · Private
IO-202, a monoclonal antibody that inhibits LILRB4 signaling to treat monocytic acute myeloid leukemia and chronic myelomonocytic leukemia
immune-onc.com →- Grants
- $3.2M
- 2 awards
- Sector median: 1
- Raised
- $7.0M
- 1 Form D · Sep 2016
- 120 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 22
- 3 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $7,003,890 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML) | $2,140,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Non-clinical Combination Pharmacology Studies and Phase 1 Clinical Development of IO-202 in Acute Myeloid Leukemia (AML) | $1,070,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2369 | Merida Biosciences | — | — |
| 2370 | 3D HEALTH SOLUTIONS, INC. | — | — |
| 2371 | Helicore, LLC | — | $2.0M |
| 2372 | IMMUNE-ONC THERAPEUTICS, INC. | — | $7.0M |
| 2373 | Eluciderm Inc. | — | $3.8M |
| 2374 | BIO-PATH HOLDINGS, INC. | — | $18M |
| 2375 | Indapta Therapeutic | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Xiaoling Charlene LiaoDirector · Executive Officer
- Liqun LuoDirector
- Guo-Liang YuDirector
Patents
- Novel ANTI-LILRB4 Antibodies And Derivative Productsapplication
- Novel LILRB2 Antibodies And Uses Thereofgranted
- Novel ANTI-LILRB4 Antibodies And Derivative Productsgranted
- Novel LILRB4 Antibodies And Uses Thereofapplication
- Combination Therapy Of Lilrb Antagonist And PD-1/PD-L1 Axis Inhibitorapplication
- Novel LILRB4 Antibodies And Uses Thereofgranted
- Novel ANTI-LILRB2 Antibodies And Derivative Productsapplication
- Novel LILRB2 Antibodies And Uses Thereofapplication
- Novel ANTI-LILRB2 Antibodies And Derivative Productsapplication
- Novel ANTI-LILRB2 Antibodies And Derivative Productsapplication
- Novel ANTI-LILRB4 Antibodies And Derivative Productsapplication
- Novel LILRB2 Antibodies And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.